A structured methodology exists to predict the likelihood of neurotoxic effects stemming from pharmaceutical compounds during their development phase. This methodology assigns values based on various preclinical assessments, integrating findings from in vitro and in vivo studies to produce a final, composite risk assessment. The output represents a tiered stratification of potential neurotoxicity, ranging from low to high concern.
The benefit of employing such an approach is the potential to identify and mitigate potential neurotoxic liabilities early in the drug development pipeline. This proactive identification can save resources by preventing investment in compounds likely to fail due to central nervous system adverse effects. Moreover, its implementation helps enhance patient safety by flagging compounds that warrant closer scrutiny during clinical trials or necessitate further refinement of dosage regimens.
